Metastatic Castration Resistant Prostate Cancer Clinical Trial
Official title:
Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). 177Lu-PSMA is a compound that binds to the extra-cellular domain of the prostate-specific membrane antigen. Pembrolizumab is an antibody targeted against anti-programmed cell death 1 (PD-1).This is a single arm study where all patients will be treated with 177Lu-PSMA for upto 6 doses and pembrolizumab for upto 35 cycles.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02495974 -
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
||
| Completed |
NCT03641560 -
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 4 | |
| Terminated |
NCT02441517 -
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT03454750 -
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
|
Phase 2 | |
| Completed |
NCT03776968 -
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT02471469 -
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
|
||
| Terminated |
NCT03177187 -
Combination Study of AZD5069 and Enzalutamide.
|
Phase 1/Phase 2 | |
| Terminated |
NCT03531827 -
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
|
Phase 2 | |
| Completed |
NCT02566772 -
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT03829436 -
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT05241613 -
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Recruiting |
NCT05369000 -
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02975934 -
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
|
Phase 3 | |
| Active, not recruiting |
NCT04869488 -
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00428220 -
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
N/A | |
| Completed |
NCT04056754 -
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT03042312 -
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
|
Phase 2 | |
| Completed |
NCT02991911 -
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02655822 -
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
|
Phase 1 | |
| Completed |
NCT02426333 -
Optimizing Abiraterone Therapy
|